Urolithin A and Immune Health, A Breakthrough Trial

Lausanne, Switzerland – October 31, 2025 – Timeline (Amazentis SA), the Swiss longevity biotech company behind Mitopure® (Urolithin A), today announced results from MitoImmune, a randomized, placebo-controlled human clinical trial in which 1,000 mg of Mitopure® daily for 4 weeks was associated with improvements in mitochondrial health of immune cells, favorable shifts in T-cell populations (including naïve cells), and markers of healthy immune function in healthy, middle-aged adults††.^[1]

The results are the first published evidence that a mitochondria-targeting supplement can measurably affect immune aging in humans. The findings, published in the peer-reviewed journal Nature Aging, build on Timeline’s muscle-health research.

The first-in-class clinical results from the MitoImmune study, now published in the prestigious journal Nature Aging, validate for the first time that the mitochondrial enhancer Mitopure (Urolithin A) enhanced immune fitness in humans at a 1000mg daily dose.†† The 4-week study showed that Mitopure supported immune health by helping maintain levels of naïve T cells, which naturally decline with age††.^[2]

“Timeline is building the most clinically researched longevity consumer company in the world.” Chris Rinsch, PhD, Co-Founder and President of Timeline

How Much Clinical Research Stands Behind Mitopure?

Over the past 18 years, Timeline has invested more than $50 million in research and clinical development, resulting in 25 registered human trials and over 80 patents centered around its proprietary ingredient Mitopure.

Mitopure is the only Urolithin A supplement supported by multiple placebo-controlled human clinical trials and validated through third-party testing.

Mitopure is a postbiotic that is clinically proven to trigger mitophagy, the body's cellular recycling process for mitochondria.^[3] Earlier this year, Timeline’s cutting-edge research was recognized as a top 40 winner in the Healthspan award by the XPRIZE. Learn more about the benefits of Mitopure.

What Did the MitoImmune Study Find About Urolithin A and Immune Health?

The MitoImmune study is a 4-week, double-blind, placebo-controlled trial of 50 healthy adults aged 45 to 70. 1,000 mg of Mitopure daily was associated with improvements in mitochondrial health of immune cells, favorable shifts in T-cell populations (including naïve cells), and markers of healthy immune function††.^[4] Compared with placebo, the Mitopure group showed these results††:^[5]

• More naïve T cells, which naturally decline with age
• Better fuel use and new mitochondria in CD8 T cells, key effector cells of the immune system
• Support for NK cells and non-classical monocytes, including better bacterial uptake in lab tests
• Well tolerated, with no serious side effects

“As we age, our immune system naturally becomes less effective. What’s remarkable here is that Urolithin A shows the potential to rejuvenate immune function by improving mitochondrial health, a completely new approach with real implications for healthy aging and quality of life.”Professor Florian Greten, MD, principal investigator and Director of the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus

“It’s rare to see a supplement show measurable effects on immune aging in such a short time. By targeting the foundational cellular changes in immune cells instead of a temporary seasonal boost with Vitamin C for example, Urolithin A offers a unique way to help rejuvenate immune function, something that no other supplement has demonstrated at this level.”Collaborator Dr. Eric Verdin, MD, President and CEO of the Buck Institute of Aging

What’s Next for Mitopure Research?

To further investigate its potential on immune aging, Mitopure is now being evaluated in a follow-up clinical trial led by oncologist Dr. Fabian Acker, MD, at Goethe University, testing its role as a nutritional supplement in cancer patients.^[6]

About Timeline®

Timeline (parent company Amazentis) is a pioneering Swiss health science company committed to revolutionizing the longevity industry with its groundbreaking, clinically proven, proprietary ingredient Mitopure®. Offering a comprehensive approach to cellular health, Timeline incorporates the benefits of Mitopure inside its next-generation nutritional supplements and topical skin health products. With more than a decade of expertise in aging science research, Timeline seeks to push the boundaries of human healthspan, contributing to a future where everyone can live longer, healthier lives. The company is backed by over 15 years of research by distinguished scientists, multiple clinical studies, and 50+ global patents. Nestlé Health Science and L’Oréal are investors in the company.

About MitoImmune

Title: Nature Aging “Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial”

DOI: 10.1038/s43587-025-00996-x

Frequently Asked Questions

Does Urolithin A improve immune fitness in aging adults?

Yes. In Timeline’s MitoImmune trial, four weeks of daily Mitopure® (Urolithin A) supplementation helps maintain healthy immune function with age, compared with placebo in middle-aged adults.^[7] The results were peer-reviewed and published in Nature Aging, the first published human trial linking a mitochondria-targeting supplement to measurable immune-aging benefits. The trial included 50 participants; Timeline and independent researchers are continuing to study Urolithin A’s effects on immune health in larger and longer trials.

What is the difference between Mitopure and generic Urolithin A?

Mitopure® is Timeline’s proprietary, clinically studied form of Urolithin A, the postbiotic compound that activates mitophagy, the cellular process that clears damaged mitochondria. Unlike generic Urolithin A supplements, Mitopure has been evaluated in Timeline’s own clinical trial program, including the MitoImmune immune-health study and prior muscle-health research. Formulation and bioavailability can vary across other brands of Urolithin Also the clinical evidence behind a specific brand should be checked before comparing claims.

Where can I read the full MitoImmune study?

The MitoImmune study is published in Nature Aging under the title “Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.”^[8] It is a peer-reviewed, placebo-controlled clinical trial in 50 middle-aged adults. Readers can access the paper directly via its DOI, listed in the citation for this article.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

††Our randomized, placebo-controlled clinical study showed that supplementation with Mitopure 1,000 mg for 4 weeks was associated with improvements in mitochondrial health of immune cells, favorable shifts in T-cell populations (including naïve cells), and markers of healthy immune function in healthy, middle-aged adults.